Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 2/2015

01-02-2015 | Review

Mechanisms underlying weight loss and metabolic improvements in rodent models of bariatric surgery

Authors: Deanna M. Arble, Darleen A. Sandoval, Randy J. Seeley

Published in: Diabetologia | Issue 2/2015

Login to get access

Abstract

Obesity is a growing health risk with few successful treatment options and fewer still that target both obesity and obesity-associated comorbidities. Despite ongoing scientific efforts, the most effective treatment option to date was not developed from basic research but by surgeons observing outcomes in the clinic. Bariatric surgery is the most successful treatment for significant weight loss, resolution of type 2 diabetes and the prevention of future weight gain. Recent work with animal models has shed considerable light on the molecular underpinnings of the potent effects of these ‘metabolic’ surgical procedures. Here we review data from animal models and how these studies have evolved our understanding of the critical signalling systems that mediate the effects of bariatric surgery. These insights could lead to alternative therapies able to accomplish effects similar to bariatric surgery in a less invasive manner.
Literature
1.
Shields M, Carroll MD, Ogden CL (2011) Adult obesity prevalence in Canada and the United States. NCHS Data Brief: 1–8
2.
3.
Kraschnewski JL, Boan J, Esposito J et al (2010) Long-term weight loss maintenance in the United States. Int J Obes (Lond) 34:1644–1654
4.
Bray GA (2008) Lifestyle and pharmacological approaches to weight loss: efficacy and safety. J Clin Endocrinol Metab 93:S81–S88PubMedCentralPubMed
5.
Sandoval D (2011) Bariatric surgeries: beyond restriction and malabsorption. Int J Obes (Lond) 35(Suppl 3):S45–S49
6.
Pories WJ, Swanson MS, MacDonald KG et al (1995) Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222:339–350, discussion 350–332PubMedCentralPubMed
7.
Cohen RV, Rubino F, Schiavon C, Cummings DE (2012) Diabetes remission without weight loss after duodenal bypass surgery. Surg Obes Relat Dis 8:e66–e68PubMedCentralPubMed
8.
Stefater MA, Wilson-Perez HE, Chambers AP, Sandoval DA, Seeley RJ (2012) All bariatric surgeries are not created equal: insights from mechanistic comparisons. Endocr Rev 33:595–622PubMedCentralPubMed
9.
Moshiri M, Osman S, Robinson TJ, Khandelwal S, Bhargava P, Rohrmann CA (2013) Evolution of bariatric surgery: a historical perspective. AJR Am J Roentgenol 201:W40–W48PubMed
10.
Chambers AP, Stefater MA, Wilson-Perez HE et al (2011) Similar effects of roux-en-Y gastric bypass and vertical sleeve gastrectomy on glucose regulation in rats. Physiol Behav 105:120–123PubMed
11.
Chambers AP, Jessen L, Ryan KK et al (2011) Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology 141:950–958PubMedCentralPubMed
12.
Wickremesekera K, Miller G, Naotunne TD, Knowles G, Stubbs RS (2005) Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg 15:474–481PubMed
13.
Bal BS, Finelli FC, Koch TR (2011) Origins of and recognition of micronutrient deficiencies after gastric bypass surgery. Curr Diabetes Rep 11:136–141
14.
Stemmer K, Bielohuby M, Grayson BE et al (2013) Roux-en-Y gastric bypass surgery but not vertical sleeve gastrectomy decreases bone mass in male rats. Endocrinology 154:2015–2024PubMed
15.
Santry HP, Gillen DL, Lauderdale DS (2005) Trends in bariatric surgical procedures. JAMA 294:1909–1917PubMed
16.
Abu-Jaish W, Rosenthal RJ (2010) Sleeve gastrectomy: a new surgical approach for morbid obesity. Expert Rev Gastroenterol Hepatol 4:101–119PubMed
17.
Rizzello M, Abbatini F, Casella G et al (2010) Early postoperative insulin-resistance changes after sleeve gastrectomy. Obes Surg 20:50–55PubMed
18.
Basso N, Capoccia D, Rizzello M et al (2011) First-phase insulin secretion, insulin sensitivity, ghrelin, GLP-1, and PYY changes 72 h after sleeve gastrectomy in obese diabetic patients: the gastric hypothesis. Surg Endosc 25:3540–3550PubMed
19.
Nannipieri M, Baldi S, Mari A et al (2013) Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab 98:4391–4399PubMed
20.
Buchwald H, Estok R, Fahrbach K et al (2009) Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122:248–256PubMed
21.
Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA (2014) The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg 149:275–287PubMed
22.
Trastulli S, Desiderio J, Guarino S et al (2013) Laparoscopic sleeve gastrectomy compared with other bariatric surgical procedures: a systematic review of randomized trials. Surg Obes Relat Dis 9:816–829PubMed
23.
Lee WJ, Chong K, Ser KH et al (2011) Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg 146:143–148PubMed
24.
Schauer PR, Bhatt DL, Kirwan JP et al (2014) Bariatric surgery versus intensive medical therapy for diabetes – 3-year outcomes. N Engl J Med 370:2002–2013
25.
Pham S, Gancel A, Scotte M et al (2014) Comparison of the effectiveness of four bariatric surgery procedures in obese patients with type 2 diabetes: a retrospective study. J Obes 2014:638203PubMedCentralPubMed
26.
Guijarro A, Osei-Hyiaman D, Harvey-White J et al (2008) Sustained weight loss after Roux-en-Y gastric bypass is characterized by down regulation of endocannabinoids and mitochondrial function. Ann Surg 247:779–790PubMedCentralPubMed
27.
Abd Ellatif ME, Abdallah E, Askar W et al (2014) Long term predictors of success after laparoscopic sleeve gastrectomy. Int J Surg 12:504–508PubMed
28.
Sjöström L, Peltonen M, Jacobson P et al (2014) Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311:2297–2304PubMed
29.
Chambers AP, Kirchner H, Wilson-Perez HE et al (2013) The effects of vertical sleeve gastrectomy in rodents are ghrelin independent. Gastroenterology 144:50–52PubMedCentralPubMed
30.
Stefater MA, Perez-Tilve D, Chambers AP et al (2010) Sleeve gastrectomy induces loss of weight and fat mass in obese rats, but does not affect leptin sensitivity. Gastroenterology 138:2426–2436PubMedCentralPubMed
31.
Carey DG, Pliego GJ, Raymond RL (2006) Body composition and metabolic changes following bariatric surgery: effects on fat mass, lean mass and basal metabolic rate: six months to one-year follow-up. Obes Surg 16:1602–1608PubMed
32.
Wilson-Perez HE, Chambers AP, Ryan KK et al (2013) Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide 1 receptor deficiency. Diabetes 62:2380–2385PubMedCentralPubMed
33.
Nestoridi E, Kvas S, Kucharczyk J, Stylopoulos N (2012) Resting energy expenditure and energetic cost of feeding are augmented after Roux-en-Y gastric bypass in obese mice. Endocrinology 153:2234–2244PubMed
34.
Lopez PP, Nicholson SE, Burkhardt GE, Johnson RA, Johnson FK (2009) Development of a sleeve gastrectomy weight loss model in obese Zucker rats. J Surg Res 157:243–250PubMedCentralPubMed
35.
Liu B, Kuang L, Liu J (2014) Bariatric surgery relieves type 2 diabetes and modulates inflammatory factors and coronary endothelium eNOS/iNOS expression in db/db mice. Can J Physiol Pharmacol 92:70–77PubMed
36.
Grayson BE, Schneider KM, Woods SC, Seeley RJ (2013) Improved rodent maternal metabolism but reduced intrauterine growth after vertical sleeve gastrectomy. Sci Transl Med 5:199ra112PubMedCentralPubMed
37.
Meguid MM, Glade MJ, Middleton FA (2008) Weight regain after Roux-en-Y: a significant 20% complication related to PYY. Nutrition 24:832–842PubMed
38.
Stylopoulos N, Hoppin AG, Kaplan LM (2009) Roux-en-Y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats. Obesity 17:1839–1847PubMedCentralPubMed
39.
Shah SS, Todkar JS, Shah PS, Cummings DE (2010) Diabetes remission and reduced cardiovascular risk after gastric bypass in Asian Indians with body mass index <35 kg/m2. Surg Obes Relat Dis 6:332–338PubMedCentralPubMed
40.
Cummings DE, Overduin J, Foster-Schubert KE (2004) Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 89:2608–2615PubMed
41.
Chambers AP, Smith EP, Begg DP et al (2014) Regulation of gastric emptying rate and its role in nutrient-induced GLP-1 secretion in rats after vertical sleeve gastrectomy. Am J Physiol Endocrinol Metab 306:E424–E432PubMed
42.
Odstrcil EA, Martinez JG, Santa Ana CA et al (2010) The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. Am J Clin Nutr 92:704–713PubMed
43.
Schwartz A, Doucet E (2010) Relative changes in resting energy expenditure during weight loss: a systematic review. Obes Rev Off J Int Assoc Study Obes 11:531–547
44.
Corbett SW, Stern JS, Keesey RE (1986) Energy expenditure in rats with diet-induced obesity. Am J Clin Nutr 44:173–180PubMed
45.
Warde-Kamar J, Rogers M, Flancbaum L, Laferrere B (2004) Calorie intake and meal patterns up to 4 years after Roux-en-Y gastric bypass surgery. Obes Surg 14:1070–1079PubMed
46.
Carrasco F, Papapietro K, Csendes A et al (2007) Changes in resting energy expenditure and body composition after weight loss following Roux-en-Y gastric bypass. Obes Surg 17:608–616PubMed
47.
Rubino F, R'Bibo SL, del Genio F, Mazumdar M, McGraw TE (2010) Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. Nat Rev Endocrinol 6:102–109PubMedCentralPubMed
48.
Rubino F, Gagner M, Gentileschi P et al (2004) The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240:236–242PubMedCentralPubMed
49.
Jackness C, Karmally W, Febres G et al (2013) Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and beta-cell function in type 2 diabetic patients. Diabetes 62:3027–3032PubMedCentralPubMed
50.
Bradley D, Conte C, Mittendorfer B et al (2012) Gastric bypass and banding equally improve insulin sensitivity and beta cell function. J Clin Invest 122:4667–4674PubMedCentralPubMed
51.
Abbatini F, Rizzello M, Casella G et al (2010) Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes. Surg Endosc 24:1005–1010PubMed
52.
Magkos F, Bradley D, Schweitzer GG et al (2013) Effect of Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding on branched-chain amino acid metabolism. Diabetes 62:2757–2761PubMedCentralPubMed
53.
Nannipieri M, Mari A, Anselmino M et al (2011) The role of beta-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J Clin Endocrinol Metab 96:E1372–E1379PubMed
54.
Romero F, Nicolau J, Flores L et al (2012) Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surg Endosc 26:2231–2239PubMed
55.
Previs SF, Brunengraber DZ, Brunengraber H (2009) Is there glucose production outside of the liver and kidney? Annu Rev Nutr 29:43–57PubMed
56.
Troy S, Soty M, Ribeiro L et al (2008) Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab 8:201–211PubMed
57.
Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8:728–742PubMed
58.
Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ (1994) Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metab Clin Exp 43:104–108PubMed
59.
Sandoval DA, Bagnol D, Woods SC, D’Alessio DA, Seeley RJ (2008) Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 57:2046–2054PubMedCentralPubMed
60.
Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH, Drucker DJ (2009) The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 150:1155–1164PubMedCentralPubMed
61.
Turton MD, O’Shea D, Gunn I et al (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69–72PubMed
62.
Gutzwiller JP, Degen L, Heuss L, Beglinger C (2004) Glucagon-like peptide 1 (GLP-1) and eating. Physiol Behav 82:17–19PubMed
63.
Mokadem M, Zechner JF, Margolskee RF, Drucker DJ, Aguirre V (2014) Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. Mol Metab 3:191–201PubMedCentralPubMed
64.
Bode B (2011) Liraglutide: a review of the first once-daily GLP-1 receptor agonist. Am J Manage Care 17:S59–S70
65.
Pratley R, Nauck M, Bailey T et al (2011) One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 65:397–407PubMedCentralPubMed
66.
Fujishima Y, Maeda N, Inoue K et al (2012) Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol 11:107PubMedCentralPubMed
67.
Jiménez A, Mari A, Casamitjana R, Lacy A, Ferrannini E, Vidal J (2014) GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type 2 diabetes. Diabetes 63:3372–3377
68.
Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ (2006) PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 291:R367–R375PubMed
69.
Peterli R, Wolnerhanssen B, Peters T et al (2009) Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 250:234–241PubMed
70.
Shin AC, Zheng H, Townsend RL, Sigalet DL, Berthoud HR (2010) Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery. Endocrinology 151:1588–1597PubMedCentralPubMed
71.
Chandarana K, Gelegen C, Karra E et al (2011) Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY. Diabetes 60:810–818PubMedCentralPubMed
72.
Wren AM, Small CJ, Ward HL et al (2000) The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141:4325–4328PubMed
73.
Wren AM, Seal LJ, Cohen MA et al (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992PubMed
74.
Tschop M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407:908–913PubMed
75.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660PubMed
76.
Lai KC, Cheng CH, Leung PS (2007) The ghrelin system in acinar cells: localization, expression, and regulation in the exocrine pancreas. Pancreas 35:e1–e8PubMed
77.
Bohdjalian A, Langer FB, Shakeri-Leidenmuhler S et al (2010) Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg 20:535–540PubMed
78.
Wang Y, Liu J (2009) Plasma ghrelin modulation in gastric band operation and sleeve gastrectomy. Obes Surg 19:357–362PubMed
79.
Cummings DE, Weigle DS, Frayo RS et al (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346:1623–1630PubMed
80.
Tymitz K, Engel A, McDonough S, Hendy MP, Kerlakian G (2011) Changes in ghrelin levels following bariatric surgery: review of the literature. Obes Surg 21:125–130PubMed
81.
Leibel RL, Rosenbaum M, Hirsch J (1995) Changes in energy expenditure resulting from altered body weight. N Engl J Med 332:621–628PubMed
82.
Korner J, Bessler M, Cirilo LJ et al (2005) Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 90:359–365PubMed
83.
Woelnerhanssen B, Peterli R, Steinert RE, Peters T, Borbely Y, Beglinger C (2011) Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy—a prospective randomized trial. Surg Obes Relat Dis 7:561–568PubMed
84.
Schultes B, Ernst B, Wilms B, Thurnheer M, Hallschmid M (2010) Hedonic hunger is increased in severely obese patients and is reduced after gastric bypass surgery. Am J Clin Nutr 92:277–283PubMed
85.
Buchwald H, Avidor Y, Braunwald E et al (2004) Bariatric surgery: a systematic review and meta-analysis. JAMA 292:1724–1737PubMed
86.
Hady HR, Dadan J, Luba M (2012) The influence of laparoscopic sleeve gastrectomy on metabolic syndrome parameters in obese patients in own material. Obes Surg 22:13–22PubMedCentralPubMed
87.
Nguyen NT, Varela E, Sabio A, Tran CL, Stamos M, Wilson SE (2006) Resolution of hyperlipidemia after laparoscopic Roux-en-Y gastric bypass. J Am Coll Surg 203:24–29PubMed
88.
Stefater MA, Sandoval DA, Chambers AP et al (2011) Sleeve gastrectomy in rats improves postprandial lipid clearance by reducing intestinal triglyceride secretion. Gastroenterology 141(939–949):e931–e934
89.
Myronovych A, Kirby M, Ryan KK et al (2014) Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner. Obesity 22:390–400PubMedCentralPubMed
90.
Wang PY, Caspi L, Lam CK et al (2008) Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature 452:1012–1016PubMed
91.
Bueter M, Lowenstein C, Olbers T et al (2010) Gastric bypass increases energy expenditure in rats. Gastroenterology 138:1845–1853PubMed
92.
Chambers AP, Wilson-Perez HE, McGrath S et al (2012) Effect of vertical sleeve gastrectomy on food selection and satiation in rats. Am J Physiol Endocrinol Metab 303:E1076–E1084PubMedCentralPubMed
93.
Zheng H, Shin AC, Lenard NR et al (2009) Meal patterns, satiety, and food choice in a rat model of Roux-en-Y gastric bypass surgery. Am J Physiol Regul Integr Comp Physiol 297:R1273–R1282PubMedCentralPubMed
94.
Colles SL, Dixon JB (2006) Night eating syndrome: impact on bariatric surgery. Obes Surg 16:811–820PubMed
95.
Wilson-Perez HE, Chambers AP, Sandoval DA et al (2013) The effect of vertical sleeve gastrectomy on food choice in rats. Int J Obes (Lond) 37:288–295
96.
le Roux CW, Bueter M, Theis N et al (2011) Gastric bypass reduces fat intake and preference. Am J Physiol Regul Integr Comp Physiol 301:R1057–R1066PubMedCentralPubMed
97.
Mul JD, Begg DP, Alsters SI et al (2012) Effect of vertical sleeve gastrectomy in melanocortin receptor 4-deficient rats. Am J Physiol Endocrinol Metab 303:E103–E110PubMedCentralPubMed
98.
Patti ME, Houten SM, Bianco AC et al (2009) Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity 17:1671–1677PubMed
99.
Parks DJ, Blanchard SG, Bledsoe RK et al (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284:1365–1368PubMed
100.
Kohli R, Kirby M, Setchell KD et al (2010) Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. Am J Physiol Gastrointest Liver Physiol 299:G652–G660PubMedCentralPubMed
101.
Cummings BP, Strader AD, Stanhope KL et al (2010) Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology 138:2437–2446PubMedCentralPubMed
102.
Kohli R, Bradley D, Setchell KD, Eagon JC, Abumrad N, Klein S (2013) Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab 98:E708–E712PubMedCentralPubMed
103.
Kohli R, Setchell KD, Kirby M et al (2013) A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology 154:2341–2351PubMedCentralPubMed
104.
Strader AD, Vahl TP, Jandacek RJ, Woods SC, D’Alessio DA, Seeley RJ (2005) Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 288:E447–E453PubMed
105.
Ryan KK, Tremaroli V, Clemmensen C et al (2014) FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509:183–188PubMedCentralPubMed
106.
Thomas C, Gioiello A, Noriega L et al (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10:167–177PubMedCentralPubMed
107.
Karlsson F, Tremaroli V, Nielsen J, Backhed F (2013) Assessing the human gut microbiota in metabolic diseases. Diabetes 62:3341–3349PubMedCentralPubMed
108.
Ley RE, Turnbaugh PJ, Klein S, Gordon JI (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444:1022–1023PubMed
109.
Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI (2005) Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 102:11070–11075PubMedCentralPubMed
110.
Schwiertz A, Taras D, Schafer K et al (2010) Microbiota and SCFA in lean and overweight healthy subjects. Obesity 18:190–195PubMed
111.
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027–1031PubMed
112.
Sweeney TE, Morton JM (2013) The human gut microbiome: a review of the effect of obesity and surgically induced weight loss. JAMA Surg 148:563–569PubMed
113.
Zhang H, DiBaise JK, Zuccolo A et al (2009) Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 106:2365–2370PubMedCentralPubMed
114.
Li JV, Ashrafian H, Bueter M et al (2011) Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut 60:1214–1223PubMedCentralPubMed
115.
Liou AP, Paziuk M, Luevano JM Jr, Machineni S, Turnbaugh PJ, Kaplan LM (2013) Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 5:178ra141
116.
Vrieze A, Van Nood E, Holleman F et al (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143:913–916PubMed
Metadata
Title
Mechanisms underlying weight loss and metabolic improvements in rodent models of bariatric surgery
Authors
Deanna M. Arble
Darleen A. Sandoval
Randy J. Seeley
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 2/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3433-3

Other articles of this Issue 2/2015

Diabetologia 2/2015 Go to the issue

Letter

Surrogate measures of insulin sensitivity vs the hyperinsulinaemic–euglycaemic clamp: a meta-analysis. Are there not some surrogate indexes lost in this story? Reply to Bastard JP, Rabasa-Lhoret R, Laville M and Disse E [letter]

Article

Nutritional strategy to prevent fatty liver and insulin resistance independent of obesity by reducing glucose-dependent insulinotropic polypeptide responses in mice

Commentary

Surrogate measures of insulin resistance: does one size fit all?

Article

Beta cell regeneration after single-round immunological destruction in a mouse model

Article

A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models

Article

Beneficial effect of a high number of copies of salivary amylase AMY1 gene on obesity risk in Mexican children
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits